Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.

about

SGLT2 Inhibition in a Kidney with Reduced Nephron Number: Modeling and Analysis of Solute Transport and Metabolism.

P2860

Q47557423-AD887E5A-1A2C-4614-8799-DE16DA8C2791

P2860

Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.

Item

http://www.wikidata.org/entity/Q50103024

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.

@en

Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.

@nl

type

Item

label

Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.

@en

Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.

@nl

prefLabel

Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.

@en

Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.

@nl

P1476

Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.

@en

P2093

Anita T Layton

http://www.w3.org/2001/XMLSchema#string

Volker Vallon

http://www.w3.org/2001/XMLSchema#string

P2860

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.

Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats.

SGLT2 Inhibition in a Kidney with Reduced Nephron Number: Modeling and Analysis of Solute Transport and Metabolism.

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.

Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

P304

e13050

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1111/APHA.13050

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

222

http://www.w3.org/2001/XMLSchema#string

P50

Volker Vallon

Anita T Layton

P577

2018-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29424089

http://www.w3.org/2001/XMLSchema#string

P932

5867254

http://www.w3.org/2001/XMLSchema#string

Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.

about

P2860

P2860

Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932